


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Date Submitted: August 27, 2002

(use as many sheets as necessary)

Sheet 1 of 3

**Complete if Known**

Application Number 09/851,327  
Filing Date 05/09/2001  
First Named Inventor Robert J. LEVY et al.  
Group Art Unit 1645-1632  
Examiner Name Unassigned  
Attorney Docket Number 047172-0170

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

RECEIVED

AUG 28 2002

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
SDP	A1	WO	01/51092	✓	A2 UNIVERSITY OF WASHINGTON	07/19/2001		
✓	A2	WO	99/34831	✓	A1 UNIVERSITY OF WASHINGTON	07/15/1999		

TECH CENTER 1600/2800

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
SDP	A3	FASBENDER, et al., "Complexes of Adenovirus with Polycationic Polymers and Cationic Lipids Increase the Efficiency of Gene Transfer <i>in Vitro</i> and <i>in Vivo</i> ," <i>The Journal of Biological Chemistry</i> , Vol. 272, No. 10, pp. 6479-6489 (1997), The American Society for Biochemistry and Molecular Biology, Inc., USA	
✓	A4	UHLMANN, et al., "Chemical Reviews," <i>Antisense Oligonucleotides: A New Therapeutic Principle</i> , Vol. 90, Number 4, pp. 544-584 (1990), The American Chemical Society, USA	
✓	A5	SCHNEIDER, et al., "Building Blocks for Oligonucleotide Analogs with Dimethylene-Sulfide, -Sulfoxide, and - Sulfone Groups Replacing Phosphodiester Link Ages," <i>Tetrahedron Letters</i> , Vol. 31, No. 3, pp. 335-338 (1990), Pergamon Press plc, UK	
✓	A6	LOW, et al., "Complete amino acid sequence of bovine thymosin $\beta_4$ : A thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations," <i>Proc. Natl. Acad. Sci.</i> , Vol. 78, No. 2, pp. 1162-1166, (1981), Immunology, USA	
✓	A7	SAFER, et al., "Isolation of a 5-kilodalton actin-sequestering peptide from human blood platelets," <i>Proc. Natl. Acad. Sci.</i> , Vol. 87, pp. 2536-2540, (1990), Cell Biology, USA	
✓	A8	LOW, et al., "Thymic Hormones and Peptides," <i>Methods in Enzymology</i> , Vol. 116, pp. 248-255, (1985), Academic Press, USA	

Examiner  
Signature

Scott D. Pritch

Date  
Considered

11/21/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Date Submitted: August 27, 2002

Use as many sheets as necessary)

2 of 3

**Complete if Known**

Application Number	09/851,327
Filing Date	05/09/2001
First Named Inventor	Robert J. LEVY et al.
Group Art Unit	1646-1632
Examiner Name	Unassigned
Attorney Docket Number	047172-0170

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
SDP	A9	NACHMIAS, et al., "Small actin-binding proteins: the $\beta$ -thymosin family," <i>Cell Biology</i> , Vol. 5, pp. 56-62 (1993), Current Biology Ltd, USA	
	A10	BRADKE, et al., "The Role of Local Actin Instability in Axon Formation," <i>Science</i> , Vol. 283, pp. 1931-1934 (1999), American Association for the Advancement of Science, USA	
	A11	COOPER, et al., "Effects of Cytochalasin and Phalloidin on Actin," <i>The Journal of Cell Biology</i> , Vol. 105, pp. 1473-1478, (1987) The Rockefeller University Press, USA	
	A12	ORKIN, et al., "Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy," pp. 1-49 (1995), National Institute of Health, USA	
	A13	INDAR, et al., "Current concepts in immunotherapy for the treatment of colorectal cancer," <i>J.R. Coll. Edinb.</i> , Vol. 47, pp. 458-474 (2002), The Royal College of Surgeons of Edinburgh, Great Britain	
	A14	DE KLEIJN, et al., "Biological therapy of colorectal cancer," <i>European Journal of Cancer</i> , Vol. 38, pp. 1022 (2002), Pergamon Press, The Netherlands	
	A15	BEHR, et al., "Radioimmunotherapy of Small-Volume Disease of Metastatic Colorectal Cancer," <i>Cancer</i> , Vol. 94, Number 4, pp. 1373-1381 (2002), American Cancer Society, USA	
	A16	STEIN, et al., "Combining Radioimmunotherapy and Chemotherapy for Treatment of Medullary Thyroid Carcinoma," <i>Cancer</i> , Vol. 94, Number 1, pp. 51-61 (2002), American Cancer Society, USA	
	A17	BEHR, et al., "Improved Treatment of Medullary Thyroid Cancer in a Nude Mouse Model by Combined Radioimmunotherapy: Doxorubicin Potentiates the Therapeutic Efficacy of radiolabeled Antibodies in a Radioresistant Tumor Type," <i>Cancer Research</i> , Vol. 57, pp. 5309-5319 (1997), American Association for Cancer Research, USA	
	A18	STEIN, et al., "Carcinoembryonic Antigen as a Target for Radioimmunotherapy of Human Medullary Thyroid Carcinoma: Antibody Processing, Targeting, and Experimental Therapy with <sup>131</sup> I and <sup>90</sup> Y Labeled Mabs," <i>Cancer Biotherapy &amp; Radiopharmaceuticals</i> , Vol. 14, Number 1, pp. 37-47 (1999), Mary Ann Liebert, Inc., USA	
	A19	KINUYA, et al., "Efficacy, toxicity and mode of interaction of combination radioimmunotherapy with 5-fluorouracil in colon cancer xenografts," <i>J Cancer Res Clin Oncol</i> , Vol. 125, pp. 630-636 (1999), Springer-Verlag, Germany	
	A20	JUWEID, et al., "Phase I/II Trial of <sup>131</sup> I-MN-14 (F(ab) <sub>2</sub> Anti-Carcinoembryonic Antigen Monoclonal Antibody in the Treatment of Patients with Metastatic Medullary Thyroid Carcinoma," <i>American Cancer Society</i> , Vol. 85, pp. 1828-1842, (1999)	
	A21	JUWEID, et al., "Prospects of Radioimmunotherapy in Epithelial Ovarian Cancer: Results with Iodine-131-Labeled Murine and Humanized MN-14 Anti-carcinoembryonic Antigen Monoclonal Antibodies <sup>1</sup> ," <i>Gynecologic Oncology</i> , Vol. 67, pp. 259-271 (1997) Article No. G0974870, Academic Press, USA	

Examiner Signature

Scott D. Priebe

Date Considered

11/21/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: August 27, 2002

(Use as many sheets as necessary)

3

of

3

**Complete if Known**

Application Number	09/851,327
Filing Date	05/09/2001
First Named Inventor	Robert J. LEVY et al.
Group Art Unit	1645 / 632
Examiner Name	Unassigned
Attorney Docket Number	047172-0170

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
SDP	A22	SPILLER, et al., "Improving the Intracellular Delivery and Molecular Efficacy of Antisense Oligonucleotides in Chronic Myeloid Leukemia Cells: A Comparison of Streptolysin-O Permeabilization, Electroporation, and Lipophilic Conjugation," <i>Blood</i> , Vol. 91, No. 12, pp. 4738-4746 (1996), The American Society of Hematology, USA	
↓	A23	MUHLRAD, et al., "Dynamic Properties of Actin," <i>The Journal of Biological Chemistry</i> , Vol. 269, No. 16, pp. 11852-11858 (1994), The Journal of Biological Chemistry, USA	
↓	A24	WANG, et al., "Cellular Factors Mediate Cadmium-Dependent Actin Depolymerization," <i>Toxicology and Applied Pharmacology</i> , Vol. 139, pp. 115-121 (1996), Academic Press, Canada	

RECEIVED

AUG 28 2002

TECH CENTER 1600/2900

Examiner  
Signature

Scott D. Pritch

Date  
Considered

11/21/02

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.